Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.
Brief Summary: There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting. This study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a vitamin K antagonist (VKA)-based antithrombotic regimen in subjects with AF following PCI with stent placement. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.


Options:
A: Arm Label: BioFreedom™ Drug Coated Stent (DCS); Type: EXPERIMENTAL; Interventions: Device: Biofreedom™ Drug Coated Stent (DCS) | Arm Label: Gazelle™ Bare Metal Coronary Stent (BMS); Type: ACTIVE_COMPARATOR; Interventions: Device: Gazelle™ Bare Metal Coronary Stent (BMS) | Intervention Type: DEVICE; Name: Biofreedom™ Drug Coated Stent (DCS); Assigned to Arm(s): BioFreedom™ Drug Coated Stent (DCS) | Intervention Type: DEVICE; Name: Gazelle™ Bare Metal Coronary Stent (BMS); Assigned to Arm(s): Gazelle™ Bare Metal Coronary Stent (BMS)
B: Arm Label: Edoxaban Regimen; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Clopidogrel, Drug: Prasugrel, Drug: Ticagrelor | Arm Label: Vitamin K Antagonist Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Prasugrel, Drug: Ticagrelor, Drug: Vitamin K antagonist | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban Regimen | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Edoxaban Regimen, Vitamin K Antagonist Regimen | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Edoxaban Regimen, Vitamin K Antagonist Regimen | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Edoxaban Regimen, Vitamin K Antagonist Regimen | Intervention Type: DRUG; Name: Vitamin K antagonist; Assigned to Arm(s): Vitamin K Antagonist Regimen
C: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Vitamin K Antagonist; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin K antagonist | Arm Label: Acetylsalicylic acid film coated tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Arm Label: Placebo matching Acetylsalicylic acid film coated tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Acetylsalicylic acid placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: vitamin K antagonist; Assigned to Arm(s): Vitamin K Antagonist | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylsalicylic acid film coated tablet | Intervention Type: OTHER; Name: Acetylsalicylic acid placebo; Assigned to Arm(s): Placebo matching Acetylsalicylic acid film coated tablet

Answer: B